Myriad Genetics, Inc. (USD) Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

Myriad Genetics, Inc. (USD) Active

320 Wakara Way, Salt Lake City, UT, US, 84108

Stock Price USD

Price Change

Last Dividend USD

C-

Latest Rating

MYGN's stock peer is ACRS (Aclaris Therapeutics, Inc.)

MYGN's stock peer is CSTL (Castle Biosciences, Inc.)

MYGN's stock peer is EXAS (Exact Sciences Corporation)

MYGN's stock peer is GH (Guardant Health, Inc.)

MYGN's stock peer is ILMN (Illumina, Inc.)

MYGN's stock peer is MEDP (Medpace Holdings, Inc.)

MYGN's stock peer is NEOG (Neogen Corporation)

MYGN's stock peer is NTRA (Natera, Inc.)

MYGN's stock peer is NVTA (Invitae Corporation)

MYGN's stock peer is OLK (Olink Holding AB (publ))

MYGN's stock peer is PSNL (Personalis, Inc.)

MYGN's stock peer is RDNT (RadNet, Inc.)

MYGN's stock peer is SHC (Sotera Health Company)

MYGN's stock peer is SYNH (Syneos Health, Inc.)

MYGN's stock peer is TWST (Twist Bioscience Corporation)

Healthcare Medical - Diagnostics & Research

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

20%

Dcf Rating

20%

Return On Equity

20%

Return On Assets

40%

Debt To Equity

20%

Price To Earnings

40%

Price To Book

Income Statement

Dividend Stats Yield is calculated via trailing-12-month period

Ex-Dividend	Payment Date	Dividend	Yield	Dividend Frequency
		1.75	6.73 %	Monthly
		1.75	4.93 %	Monthly

Recent News

Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen

Screening test provides prenatal risk assessment for common genetic conditions in one blood draw without the need for paternal testing

2025-06-03 09:00:00

Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting

Two Molecular Residual Disease (MRD) studies highlighting clinical data among seven new studies to be shared by Myriad and collaborators Two Molecular Residual Disease (MRD) studies highlighting clinical data among seven new studies to be shared by Myriad and collaborators

2025-05-27 16:05:00

Levi & Korsinsky Investigates Myriad Genetics, Inc. (MYGN) Over Possible Securities Fraud

NEW YORK, NY / ACCESS Newswire / May 27, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning possible violations of federal securities laws. Myriad released its first quarter 2025 financial results on May 6, 2025, revealing "revenue of $196 million declined by 3% year-over-year" and "pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®.

2025-05-27 10:15:00

Bronstein, Gewirtz & Grossman, LLC Encourages Myriad Genetics, Inc. (MYGN) Shareholders to Inquire about Securities Investigation

NEW YORK CITY, NY / ACCESS Newswire / May 27, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. ("Myriad Genetics, Inc." or "the Company") (NASDAQ:MYGN). Investors who purchased Myriad Genetics, Inc. securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MYGN.

2025-05-27 10:00:00

Ongoing Myriad Genetics, Inc. (MYGN) Investigation: Protect Your Rights - Contact Levi & Korsinsky

NEW YORK, NY / ACCESS Newswire / May 26, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning possible violations of federal securities laws. Myriad released its first quarter 2025 financial results on May 6, 2025, revealing "revenue of $196 million declined by 3% year-over-year" and "pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®.

2025-05-26 11:30:00

Bronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Shareholders to Connect

NEW YORK CITY, NY / ACCESS Newswire / May 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. ("Myriad Genetics, Inc." or "the Company") (NASDAQ:MYGN). Investors who purchased Myriad Genetics, Inc. securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MYGN.

2025-05-26 10:00:00

Levi & Korsinsky Investigates Myriad Genetics, Inc. (MYGN) Over Possible Securities Fraud

NEW YORK, NY / ACCESS Newswire / May 25, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning possible violations of federal securities laws. Myriad released its first quarter 2025 financial results on May 6, 2025, revealing "revenue of $196 million declined by 3% year-over-year" and "pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®.

2025-05-25 11:00:00

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Myriad Genetics, Inc. (MYGN) And Encourages Shareholders to Reach Out

NEW YORK CITY, NY / ACCESS Newswire / May 25, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. ("Myriad Genetics, Inc." or "the Company") (NASDAQ:MYGN). Investors who purchased Myriad Genetics, Inc. securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MYGN.

2025-05-25 10:00:00

ATTENTION MYGN Shareholders: Lost Money on Myriad Genetics, Inc.? Contact Levi & Korsinsky About Investigation

NEW YORK, NY / ACCESS Newswire / May 23, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning possible violations of federal securities laws. Myriad released its first quarter 2025 financial results on May 6, 2025, revealing "revenue of $196 million declined by 3% year-over-year" and "pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®.

2025-05-23 10:15:00

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Shareholders to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / May 23, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. ("Myriad Genetics, Inc." or "the Company") (NASDAQ:MYGN). Investors who purchased Myriad Genetics, Inc. securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MYGN.

2025-05-23 10:00:00

Disclaimers

StockQuay.com is not operated by a broker, dealer, or registered investment advisor. Under no circumstances should any information published on StockQuay.com be considered a recommendation to buy, sell, or hold any security. The content on this site and in its associated newsletters is intended solely for informational and educational purposes and does not constitute investment advice or financial recommendations.

Individuals or entities featured or referenced on StockQuay.com may engage in trading activity involving the securities mentioned in any article or report before or after such content is published. These individuals or entities are not affiliated with StockQuay.com, and their inclusion does not imply endorsement or accuracy of their views or actions.

StockQuay.com, its owners, or its affiliates shall not be held liable to any user or third party for any damages or losses arising from the use of content on this website. This includes, but is not limited to, investment losses, loss of profit, loss of data, missed opportunities, or indirect, incidental, or consequential damages.

Data is updated daily and is not guaranteed to be accurate or complete.

Past performance is not indicative of future results. Please conduct your own research or consult with a qualified financial advisor before making any investment decisions